269 related articles for article (PubMed ID: 17914575)
21. Identification of intronic point mutations as an alternative mechanism for p53 inactivation in lung cancer.
Takahashi T; D'Amico D; Chiba I; Buchhagen DL; Minna JD
J Clin Invest; 1990 Jul; 86(1):363-9. PubMed ID: 2164047
[TBL] [Abstract][Full Text] [Related]
22. Evidence for common clonal origin of multifocal lung cancers.
Wang X; Wang M; MacLennan GT; Abdul-Karim FW; Eble JN; Jones TD; Olobatuyi F; Eisenberg R; Cummings OW; Zhang S; Lopez-Beltran A; Montironi R; Zheng S; Lin H; Davidson DD; Cheng L
J Natl Cancer Inst; 2009 Apr; 101(8):560-70. PubMed ID: 19351924
[TBL] [Abstract][Full Text] [Related]
23. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein.
Martin AC; Facchiano AM; Cuff AL; Hernandez-Boussard T; Olivier M; Hainaut P; Thornton JM
Hum Mutat; 2002 Feb; 19(2):149-64. PubMed ID: 11793474
[TBL] [Abstract][Full Text] [Related]
24. Modulation of benzo[a]pyrene-induced p53 DNA activity by acrolein.
Biswal S; Maxwell T; Rangasamy T; Kehrer JP
Carcinogenesis; 2003 Aug; 24(8):1401-6. PubMed ID: 12807757
[TBL] [Abstract][Full Text] [Related]
25. Frequency of TP53 mutations in relation to Arg72Pro genotypes in non small cell lung cancer.
Lind H; Ekstrøm PO; Ryberg D; Skaug V; Andreassen T; Stangeland L; Haugen A; Zienolddiny S
Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):2077-81. PubMed ID: 17932356
[TBL] [Abstract][Full Text] [Related]
26. [Nuclear factor-kappaB activity and its correlation with cell proliferation in non-small cell lung cancer tissues].
Zhang J; Xu YJ; Zhang ZX; DU CL; Qiao LF; Ni W; Chen SX
Zhonghua Jie He He Hu Xi Za Zhi; 2007 Oct; 30(10):771-5. PubMed ID: 18218209
[TBL] [Abstract][Full Text] [Related]
27. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
28. In situ detection of unexpected patterns of mutant p53 gene expression in non-small cell lung cancers.
Ebina M; Martínez A; Birrer MJ; Ilona Linnoila R
Oncogene; 2001 May; 20(20):2579-86. PubMed ID: 11420668
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer.
Woenckhaus M; Merk J; Stoehr R; Schaeper F; Gaumann A; Wiebe K; Hartmann A; Hofstaedter F; Dietmaier W
Hum Pathol; 2008 Jan; 39(1):126-36. PubMed ID: 17949785
[TBL] [Abstract][Full Text] [Related]
30. TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma.
Russo A; Corsale S; Agnese V; Macaluso M; Cascio S; Bruno L; Surmacz E; Dardanoni G; Valerio MR; Vieni S; Restivo S; Fulfaro F; Tomasino RM; Gebbia N; Bazan V
J Cell Physiol; 2006 Jan; 206(1):181-8. PubMed ID: 15965904
[TBL] [Abstract][Full Text] [Related]
31. Mutations of the p53 gene in human lung cancer from chromate-exposed workers.
Kondo K; Hino N; Sasa M; Kamamura Y; Sakiyama S; Tsuyuguchi M; Hashimoto M; Uyama T; Monden Y
Biochem Biophys Res Commun; 1997 Oct; 239(1):95-100. PubMed ID: 9345276
[TBL] [Abstract][Full Text] [Related]
32. Mutations in Tp53 gene sequences from lung tumors in rats that inhaled plutonium dioxide.
Yamada Y; Oghiso Y
Radiat Res; 1999 Dec; 152(6 Suppl):S107-9. PubMed ID: 10564948
[TBL] [Abstract][Full Text] [Related]
33. Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines.
Zheng L; Wang F; Qian C; Neumann RM; Cheville JC; Tindall DJ; Liu W
Hum Mutat; 2006 Oct; 27(10):1062-3. PubMed ID: 16941491
[TBL] [Abstract][Full Text] [Related]
34. Adenomatous polyposis coli gene mutation and decreased wild-type p53 protein expression in oral submucous fibrosis: a preliminary investigation.
Liao PH; Lee TL; Yang LC; Yang SH; Chen SL; Chou MY
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):202-7. PubMed ID: 11505268
[TBL] [Abstract][Full Text] [Related]
35. TP53 gene mutations in plasma DNA of cancer patients.
Silva JM; Gonzalez R; Dominguez G; Garcia JM; España P; Bonilla F
Genes Chromosomes Cancer; 1999 Feb; 24(2):160-1. PubMed ID: 9885984
[TBL] [Abstract][Full Text] [Related]
36. p53 Cooperates berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo.
Katiyar SK; Meeran SM; Katiyar N; Akhtar S
Mol Carcinog; 2009 Jan; 48(1):24-37. PubMed ID: 18459128
[TBL] [Abstract][Full Text] [Related]
37. Frequent TP53 gene alterations (mutation, allelic loss, nuclear accumulation) in primary non-small cell lung cancer.
Shipman R; Schraml P; Colombi M; Raefle G; Dalquen P; Ludwig C
Eur J Cancer; 1996 Feb; 32A(2):335-41. PubMed ID: 8664051
[TBL] [Abstract][Full Text] [Related]
38. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
39. [Immune response to p53 protein in patients with squamous epithelial carcinoma of the upper aerodigestive tract is independent of p53 point mutation].
Gottschlich S; Maass JD; Görögh T; Lippert BM; Werner JA
Laryngorhinootologie; 1996 May; 75(5):301-5. PubMed ID: 8672215
[TBL] [Abstract][Full Text] [Related]
40. TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin's lymphoma.
Hosny G; Farahat N; Hainaut P
Cancer Lett; 2009 Mar; 275(2):234-9. PubMed ID: 19046801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
